INM has 36-month beta value of 0.70. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for INM is 3.29M, and currently, short sellers hold a 1.22% ratio of that float. The average trading volume of INM on November 06, 2024 was 6.46M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
INM) stock’s latest price update
InMed Pharmaceuticals Inc (NASDAQ: INM) has experienced a decline in its stock price by -7.41 compared to its previous closing price of 0.24. However, the company has seen a fall of -22.41% in its stock price over the last five trading days. newsfilecorp.com reported 2024-11-05 that Vancouver, British Columbia–(Newsfile Corp. – November 5, 2024) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the decision by the Nasdaq Listing Qualifications Panel (the “Panel”) to grant an exception until December 2, 2024, to implement a share consolidation to satisfy the Nasdaq Listing Rules. As previously reported by InMed on its current report on Form 8-K, on September 17, 2024, the Listing Qualifications Department (the “Nasdaq Staff”) of the Nasdaq Stock Market (“Nasdaq”) issued a determination to the Company, which was communicated through a delisting notice (the “Delisting Notice”), indicating that the Company did not satisfy the minimum $1.00 bid price per share requirement for the continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) by September 16, 2024.
INM’s Market Performance
INM’s stock has fallen by -22.41% in the past week, with a monthly rise of 4.65% and a quarterly rise of 68.79%. The volatility ratio for the week is 10.32% while the volatility levels for the last 30 days are 13.55% for InMed Pharmaceuticals Inc The simple moving average for the past 20 days is -13.94% for INM’s stock, with a -22.39% simple moving average for the past 200 days.
INM Trading at -14.87% from the 50-Day Moving Average
After a stumble in the market that brought INM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.33% of loss for the given period.
Volatility was left at 13.55%, however, over the last 30 days, the volatility rate increased by 10.32%, as shares surge +7.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.98% lower at present.
During the last 5 trading sessions, INM fell by -22.41%, which changed the moving average for the period of 200-days by -35.71% in comparison to the 20-day moving average, which settled at $0.2614. In addition, InMed Pharmaceuticals Inc saw -45.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INM starting from MANCINI ALEXANDRA DIANE JANET, who sale 240 shares at the price of $0.18 back on Jul 31 ’24. After this action, MANCINI ALEXANDRA DIANE JANET now owns 0 shares of InMed Pharmaceuticals Inc, valued at $42 using the latest closing price.
HULL ANDREW, the Director of InMed Pharmaceuticals Inc, purchase 37,500 shares at $0.39 during a trade that took place back on Feb 21 ’24, which means that HULL ANDREW is holding 38,258 shares at $14,625 based on the most recent closing price.
Stock Fundamentals for INM
Current profitability levels for the company are sitting at:
- -0.98 for the present operating margin
- 0.14 for the gross margin
The net margin for InMed Pharmaceuticals Inc stands at -0.0. The total capital return value is set at -803.46. Equity return is now at value -72.08, with -59.20 for asset returns.
Based on InMed Pharmaceuticals Inc (INM), the company’s capital structure generated 0.99 points at debt to capital in total, while cash flow to debt ratio is standing at -0.01.
Currently, EBITDA for the company is -7.45 billion with net debt to EBITDA at -0.09. When we switch over and look at the enterprise to sales, we see a ratio of 0.08. The receivables turnover for the company is 22941.26for trailing twelve months and the total asset turnover is 684.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.41.
Conclusion
To put it simply, InMed Pharmaceuticals Inc (INM) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
